Article Figures & Data
Figures
- FIGURE 1.
Typical 11C-phenytoin activity concentration images obtained in healthy subject, averaged over several early frames (30–90 s after injection) (A) and late frames (45–60 min after injection) (B).
- FIGURE 2.
Example of decay-corrected time–activity curves of 11C-phenytoin for several brain regions in healthy subject.
- FIGURE 3.
Mean and SD (error bar) of parent and polar fractions, plasma–to–whole-blood ratio (P/WB), and HPLC metabolites obtained from manual blood samples.
- FIGURE 4.
TRT variability of K1 (A) and VT (B) for each subject for small (<5 mL) and large (>5 mL) region-of-interest volumes.
- FIGURE 5.
Bland–Altman plots of K1 (A–C) and VT (D–F) test–retest data for 60- (A and D), 45- (B and E), and 30- (C and F) min scan durations. ○ = 60-min scan duration data; □ = 45-min scan duration data; △ = 30-min scan duration data; bold line = mean difference between test and retest.
- FIGURE 6.
TRT variability of K1 (A) and VT (B) for each subject and for different scan durations.
Tables
- TABLE 1
Preference Frequency (%) According to Akaike Information Criteria for Small (<5 mL) and Large (>5 mL) VOI Sizes
Akaike frequency (%) Model VOI < 5 mL VOI > 5 mL 1T2k 0.0 0.0 1T2k + Vb 31.3 42.2 2T3k 0.0 0.0 2T3k + Vb 4.6 13.8 2T4k 0.0 0.0 2T4k + Vb 4.9 3.2 - TABLE 2
TRT Variabilities for K1 and VT for Each Individual Subject, Given as Average (±SD) Percentage Repeatability Across All VOIs
Subject K1 TRT VT TRT 1 4.10 ± 4.72 2.23 ± 4.62 2 0.83 ± 5.98 −3.15 ± 6.95 3 8.76 ± 4.50 1.53 ± 6.01 4 −6.13 ± 7.71 −3.42 ± 6.78 5 −17.6 ± 7.24 −2.99 ± 13.8 6 6.51 ± 4.44 −2.46 ± 3.70 Average ± SD −0.59 ± 10.73 −1.38 ± 8.00 - TABLE 3
Summary of Correlation Parameters Between Data from Different Scan Durations (45 and 30 Minutes) Versus 60 Minutes
K1 VT Test Retest Test Retest Scan duration Slope R2 Slope R2 Slope R2 Slope R2 45 vs. 60 min 1.00 0.98 1.00 0.98 1.00 0.84 1.00 0.90 30 vs. 60 min 1.02 0.97 1.00 0.98 0.98 0.76 0.99 0.86 - TABLE 4
Comparison of Some Kinetic Parameters for 11C-Phenytoin, (R)-11C-Verapamil, and 11C-dLop
Pgp substrate K1 (mL·mL−1·min−1) k2 (min−1) VT (mL·mL−1) 11C-phenytoin (n = 6)*† 0.037 ± 0.008 0.042 ± 0.009 0.881 ± 0.126 (R)-11C-verapamil (n = 5)‡ 0.036 ± 0.009 0.102 ± 0.003 0.660 ± 0.123 11C-dLop (n = 6)* 0.014 ± 0.001 0.012 ± 0.002 1.169 ± 0.149
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Imaging the Activity of Efflux Transporters at the Blood-Brain Barrier in Neurologic Diseases: Radiotracer Selection Criteria
- Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate 11C-Metoclopramide Assessed with PET Imaging in Humans
- Parametric Methods for Dynamic 11C-Phenytoin PET Studies
- Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein
- Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide